| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
|
J Clin Oncol
|
2003
|
17.67
|
|
2
|
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
|
N Engl J Med
|
2009
|
10.54
|
|
3
|
Age and acute myeloid leukemia.
|
Blood
|
2006
|
6.46
|
|
4
|
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
|
Blood
|
2008
|
5.49
|
|
5
|
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
|
N Engl J Med
|
2014
|
5.37
|
|
6
|
JAK mutations in high-risk childhood acute lymphoblastic leukemia.
|
Proc Natl Acad Sci U S A
|
2009
|
4.98
|
|
7
|
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.
|
Nat Genet
|
2011
|
4.93
|
|
8
|
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.
|
Cancer Cell
|
2012
|
4.41
|
|
9
|
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
|
Nat Genet
|
2009
|
4.35
|
|
10
|
Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.
|
Blood
|
2010
|
4.00
|
|
11
|
Gene expression changes associated with progression and response in chronic myeloid leukemia.
|
Proc Natl Acad Sci U S A
|
2006
|
3.70
|
|
12
|
Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
|
Blood
|
2010
|
3.66
|
|
13
|
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2011
|
3.40
|
|
14
|
Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.
|
Blood
|
2009
|
2.86
|
|
15
|
The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers.
|
Nat Mater
|
2011
|
2.84
|
|
16
|
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
|
JAMA
|
2009
|
2.72
|
|
17
|
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected].
|
J Clin Oncol
|
2008
|
2.51
|
|
18
|
A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
|
Nat Med
|
2006
|
2.36
|
|
19
|
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.
|
Blood
|
2005
|
2.22
|
|
20
|
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.
|
Blood
|
2002
|
2.20
|
|
21
|
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Blood
|
2012
|
2.09
|
|
22
|
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
|
Blood
|
2010
|
2.05
|
|
23
|
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.
|
Blood
|
2012
|
1.90
|
|
24
|
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.
|
J Natl Cancer Inst
|
2013
|
1.81
|
|
25
|
BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint.
|
Nat Med
|
2013
|
1.79
|
|
26
|
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.
|
Blood
|
2008
|
1.79
|
|
27
|
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
|
Blood
|
2012
|
1.78
|
|
28
|
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Blood
|
2006
|
1.74
|
|
29
|
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.
|
Blood
|
2011
|
1.74
|
|
30
|
Metnase mediates chromosome decatenation in acute leukemia cells.
|
Blood
|
2009
|
1.74
|
|
31
|
Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.
|
Blood
|
2010
|
1.67
|
|
32
|
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.
|
Blood
|
2012
|
1.66
|
|
33
|
Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses.
|
Blood
|
2002
|
1.62
|
|
34
|
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
|
Blood
|
2012
|
1.61
|
|
35
|
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.
|
Blood
|
2012
|
1.47
|
|
36
|
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.
|
Blood
|
2006
|
1.46
|
|
37
|
Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia.
|
Blood
|
2007
|
1.46
|
|
38
|
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.
|
Nat Genet
|
2013
|
1.45
|
|
39
|
A new human natural killer leukemia cell line, IMC-1. A complex chromosomal rearrangement defined by spectral karyotyping: functional and cytogenetic characterization.
|
Leuk Res
|
2004
|
1.43
|
|
40
|
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes.
|
Blood
|
2004
|
1.41
|
|
41
|
ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.
|
J Clin Oncol
|
2012
|
1.39
|
|
42
|
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
|
Pediatr Blood Cancer
|
2011
|
1.33
|
|
43
|
Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.
|
Blood
|
2002
|
1.29
|
|
44
|
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).
|
Am J Hematol
|
2007
|
1.25
|
|
45
|
Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Blood
|
2011
|
1.25
|
|
46
|
Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation.
|
Br J Haematol
|
2008
|
1.24
|
|
47
|
Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia.
|
Blood
|
2008
|
1.20
|
|
48
|
Pediatric acute lymphoblastic leukemia.
|
Hematology Am Soc Hematol Educ Program
|
2003
|
1.13
|
|
49
|
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.
|
Br J Haematol
|
2009
|
1.13
|
|
50
|
Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group.
|
J Clin Oncol
|
2010
|
1.13
|
|
51
|
Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells.
|
Blood
|
2004
|
1.11
|
|
52
|
Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles.
|
ACS Nano
|
2011
|
1.09
|
|
53
|
Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy.
|
Blood
|
2013
|
1.08
|
|
54
|
Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers.
|
ACS Nano
|
2012
|
1.08
|
|
55
|
Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.
|
J Clin Oncol
|
2013
|
1.07
|
|
56
|
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
|
Br J Haematol
|
2004
|
1.05
|
|
57
|
Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia.
|
Genes Chromosomes Cancer
|
2005
|
1.05
|
|
58
|
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.
|
Blood
|
2010
|
1.00
|
|
59
|
Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.
|
Blood
|
2013
|
0.99
|
|
60
|
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.
|
Blood
|
2013
|
0.95
|
|
61
|
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2012
|
0.95
|
|
62
|
Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials.
|
Blood
|
2006
|
0.94
|
|
63
|
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
|
Br J Haematol
|
2014
|
0.93
|
|
64
|
Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML.
|
Blood
|
2012
|
0.92
|
|
65
|
SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia.
|
Blood
|
2012
|
0.92
|
|
66
|
Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.
|
Blood
|
2011
|
0.91
|
|
67
|
Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia.
|
Am J Med
|
2010
|
0.90
|
|
68
|
Acute myeloid leukemia.
|
Hematology Am Soc Hematol Educ Program
|
2002
|
0.89
|
|
69
|
Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase.
|
Blood
|
2002
|
0.89
|
|
70
|
Advances in the Biology of Acute Lymphoblastic Leukemia-From Genomics to the Clinic.
|
J Adolesc Young Adult Oncol
|
2011
|
0.88
|
|
71
|
All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129.
|
Leuk Res
|
2013
|
0.85
|
|
72
|
PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism.
|
Leuk Res
|
2002
|
0.83
|
|
73
|
AML1-FOG2 fusion protein in myelodysplasia.
|
Blood
|
2005
|
0.81
|
|
74
|
Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).
|
Pediatr Blood Cancer
|
2014
|
0.80
|
|
75
|
Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia.
|
Br J Haematol
|
2006
|
0.79
|
|
76
|
The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia.
|
PLoS One
|
2013
|
0.78
|
|
77
|
AACR Cancer Progress Report 2016.
|
Clin Cancer Res
|
2016
|
0.75
|
|
78
|
A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.
|
Br J Haematol
|
2013
|
0.75
|
|
79
|
Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.
|
Nature
|
2016
|
0.75
|
|
80
|
Resolution of ambiguous low-level positive quantitative polymerase chain reaction results in TEL-AML1 positive ALL using a post-PCR fluorescent oligoligation method.
|
Br J Haematol
|
2006
|
0.75
|